End of induction MRD assessment based early treatment intensification with novel agents in ETP-ALL- may be the way forward.

IF 2.3 Q2 HEMATOLOGY
Pritish Chandra Patra, Sujay Rainchwar, Reema Singh, Rohan Halder, Pallavi Mehta, Megha Verma, Rayaz Ahmed, Jyoti Shankar Raichaudhuri, Dinesh Bhurani, Narendra Agrawal, Suman Pramanik
{"title":"End of induction MRD assessment based early treatment intensification with novel agents in ETP-ALL- may be the way forward.","authors":"Pritish Chandra Patra, Sujay Rainchwar, Reema Singh, Rohan Halder, Pallavi Mehta, Megha Verma, Rayaz Ahmed, Jyoti Shankar Raichaudhuri, Dinesh Bhurani, Narendra Agrawal, Suman Pramanik","doi":"10.5045/br.2023.2022241","DOIUrl":null,"url":null,"abstract":"TO THE EDITOR: Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) arises from early thymic progenitor cells that migrate from the bone marrow to the thymus and have the potential to differentiate into myeloid/dendritic or T cells. Gene expression profiling has revealed that ETP cells share similarities with hematopoietic stem cells and myeloid progenitor cells. ETP leukemic cells do not express CD1a, CD8, and CD5 (negative to dim). Instead, these cells express ≥1 stem cell/myeloid markers. However, in addition to other ETP-ALL diagnostic criteria, near-ETP-ALL usually shows brighter CD5 [1]. In the literature, the data on ETP-ALL varies markedly, ranging from outcomes poorer than those of other T-ALL to comparable outcomes, with complete remission (CR) rates ranging from 70% to more than 90% [2-5]. Combination chemotherapy is the mainstay treatment. ETP-ALL represents a high-risk subtype of ALL. These outcomes highlight the need for alternative therapeutic approaches that are prognosis-based, and ideally, aiming for minimal residual disease (MRD)negative remission, which may help in preventing relapse. Here, we present the results of a retrospective study on ETP/near-ETP-ALL in the Department of Hemato-Oncology of a dedicated cancer hospital in North India.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7a/7a/br-58-2-112.PMC10310492.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5045/br.2023.2022241","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

TO THE EDITOR: Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) arises from early thymic progenitor cells that migrate from the bone marrow to the thymus and have the potential to differentiate into myeloid/dendritic or T cells. Gene expression profiling has revealed that ETP cells share similarities with hematopoietic stem cells and myeloid progenitor cells. ETP leukemic cells do not express CD1a, CD8, and CD5 (negative to dim). Instead, these cells express ≥1 stem cell/myeloid markers. However, in addition to other ETP-ALL diagnostic criteria, near-ETP-ALL usually shows brighter CD5 [1]. In the literature, the data on ETP-ALL varies markedly, ranging from outcomes poorer than those of other T-ALL to comparable outcomes, with complete remission (CR) rates ranging from 70% to more than 90% [2-5]. Combination chemotherapy is the mainstay treatment. ETP-ALL represents a high-risk subtype of ALL. These outcomes highlight the need for alternative therapeutic approaches that are prognosis-based, and ideally, aiming for minimal residual disease (MRD)negative remission, which may help in preventing relapse. Here, we present the results of a retrospective study on ETP/near-ETP-ALL in the Department of Hemato-Oncology of a dedicated cancer hospital in North India.

Abstract Image

Abstract Image

基于诱导结束MRD评估的早期治疗强化使用新型药物治疗ETP-ALL-可能是前进的方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Blood Research
Blood Research HEMATOLOGY-
CiteScore
3.70
自引率
0.00%
发文量
64
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信